Lone S. Friis

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMT.

Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMT.

Journal: American journal of hematology

Published: March 09, 2026

Immune reconstitution in patients with myelofibrosis conditioned with a non-myeloablative regimen prior to allogeneic stem cell transplantation.

Immune reconstitution in patients with myelofibrosis conditioned with a non-myeloablative regimen prior to allogeneic stem cell transplantation.

Journal: Bone marrow transplantation

Published: November 19, 2025

Early high-resolution immune profiles are associated with survival, relapse and graft-versus-host-disease after allogeneic hematopoietic cell transplantation.

Early high-resolution immune profiles are associated with survival, relapse and graft-versus-host-disease after allogeneic hematopoietic cell transplantation.

Journal: Bone marrow transplantation

Published: November 18, 2025

Individualized Treosulfan-Based Conditioning Improves Outcomes of Allogeneic Hematopoietic Transplantation for Myelodysplastic Syndrome: A 25-Year Retrospective, Population-Based Analysis.

Individualized Treosulfan-Based Conditioning Improves Outcomes of Allogeneic Hematopoietic Transplantation for Myelodysplastic Syndrome: A 25-Year Retrospective, Population-Based Analysis.

Journal: Transplantation and cellular therapy

Published: September 20, 2025

Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.

Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.

Journal: Bone marrow transplantation

Published: July 24, 2025

Interleukin-15 and innate effector cells as predictors of outcome in allogeneic hematopoietic cell transplantation.

Interleukin-15 and innate effector cells as predictors of outcome in allogeneic hematopoietic cell transplantation.

Journal: Frontiers in immunology

Published: June 18, 2025

Case Series: Clinical Significance of Heterozygous Pathogenic RTEL1 Variants Identified via Routine Clinical Genetic Diagnostics.

Case Series: Clinical Significance of Heterozygous Pathogenic RTEL1 Variants Identified via Routine Clinical Genetic Diagnostics.

Journal: American journal of medical genetics. Part A

Published: April 25, 2025

Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT.

Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT.

Journal: Bone marrow transplantation

Published: February 11, 2025

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. A Population-Based Study from Eastern Denmark.

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. A Population-Based Study from Eastern Denmark.

Journal: Transplantation and cellular therapy

Published: December 13, 2024

Plasma Nucleosome Levels and Risk of Acute Graft-Versus-Host Disease After Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Cohort Study.

Plasma Nucleosome Levels and Risk of Acute Graft-Versus-Host Disease After Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Cohort Study.

Journal: Transplantation and cellular therapy

Published: December 05, 2024

Outpatient Management of Patients Conditioned with Fludarabine and Treosulfan prior to Allogeneic Hematopoietic Cell Transplantation.

Outpatient Management of Patients Conditioned with Fludarabine and Treosulfan prior to Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: September 02, 2024

Functional immune reconstitution after allogeneic hematopoietic stem cell transplantation in myeloablative and non-myeloablative conditioned patients.

Functional immune reconstitution after allogeneic hematopoietic stem cell transplantation in myeloablative and non-myeloablative conditioned patients.

Journal: Scientific reports

Published: August 20, 2024

Showing 1-12 of 56

Last Updated: 09/26/2026